Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.

Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF, Alkayed NJ.

J Neurosci. 2007 Apr 25;27(17):4642-9.

2.

Soluble epoxide hydrolase: a novel therapeutic target in stroke.

Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ.

J Cereb Blood Flow Metab. 2007 Dec;27(12):1931-40. Epub 2007 Apr 18.

3.

CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study.

Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC.

Pharmacogenet Genomics. 2007 May;17(5):349-58.

4.

Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways.

Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, Lu ZY, Wang DW, Zeldin DC.

Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H142-51. Epub 2007 Feb 23.

5.

Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis.

Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M.

Circulation. 2007 Jan 30;115(4):459-67. Epub 2007 Jan 22. Review.

6.

Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids.

Jiang JG, Chen RJ, Xiao B, Yang S, Wang JN, Wang Y, Cowart LA, Xiao X, Wang DW, Xia Y.

Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):162-74. Epub 2006 Nov 30.

PMID:
17164144
7.

Vascular endothelium and atherosclerosis.

Libby P, Aikawa M, Jain MK.

Handb Exp Pharmacol. 2006;(176 Pt 2):285-306. Review.

PMID:
16999230
8.

Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.

Stoll G, Bendszus M.

Stroke. 2006 Jul;37(7):1923-32. Epub 2006 Jun 1. Review.

9.

Emerging role of epoxyeicosatrienoic acids in coronary vascular function.

Larsen BT, Gutterman DD, Hatoum OA.

Eur J Clin Invest. 2006 May;36(5):293-300. Review.

PMID:
16634832
10.

Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study.

Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC.

Hum Mol Genet. 2006 May 15;15(10):1640-9. Epub 2006 Apr 4.

11.

Incidence and trends of stroke and its subtypes in China: results from three large cities.

Jiang B, Wang WZ, Chen H, Hong Z, Yang QD, Wu SP, Du XL, Bao QJ.

Stroke. 2006 Jan;37(1):63-8. Epub 2005 Nov 23.

12.

The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke.

Fornage M, Lee CR, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E.

Hum Mol Genet. 2005 Oct 1;14(19):2829-37. Epub 2005 Aug 22.

13.

Soluble epoxide hydrolase is a therapeutic target for acute inflammation.

Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9772-7. Epub 2005 Jun 30.

14.

Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways.

Wang Y, Wei X, Xiao X, Hui R, Card JW, Carey MA, Wang DW, Zeldin DC.

J Pharmacol Exp Ther. 2005 Aug;314(2):522-32. Epub 2005 Apr 19.

15.

Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.

Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR, Node K, Börgel J, Mügge A, Lindpaintner K, Huesing A, Maisch B, Zeldin DC, Liao JK.

Circulation. 2004 Oct 12;110(15):2132-6. Epub 2004 Oct 4.

16.

Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels.

Fang X, Weintraub NL, McCaw RB, Hu S, Harmon SD, Rice JB, Hammock BD, Spector AA.

Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2412-20. Epub 2004 Jul 29.

17.

Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways.

Wang H, Lin L, Jiang J, Wang Y, Lu ZY, Bradbury JA, Lih FB, Wang DW, Zeldin DC.

J Pharmacol Exp Ther. 2003 Nov;307(2):753-64. Epub 2003 Sep 15.

18.

Polymorphisms in human soluble epoxide hydrolase.

Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF.

Mol Pharmacol. 2003 Aug;64(2):482-90.

19.

Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats.

Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, Morisseau CH, Doris PA.

Hypertension. 2002 Oct;40(4):485-90.

20.

World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic.

Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C.

Circulation. 2002 Sep 24;106(13):1602-5. Review. No abstract available.

Supplemental Content

Support Center